Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC7720 | Indiplon |
| Potent GABAA receptor positive allosteric modulator that acts at the benzodiazepine site (Ki values are 1.2 and 1.7 nM in rat frontal cortex and cerebellum respectively). Displays ~ 10-fold selectivity for α1 subunit-containing receptors (EC50 values are 2.6, 24, 60 and 77 nM for α1β2γ2, α2β2γ2, α3β3γ2 and α5β2γ2 receptors respectively). Exhibits sedative, hypnotic, anxiolytic and anticonvulsant activity in vivo and is orally active. | |
| BCC7724 | (5Z)-7-Oxozeaenol |
| Resorcyclic lactone of fungal origin that acts as a potent and selective transforming growth factor-β-activated kinase 1 (TAK1) mitogen-activated protein kinase kinase kinase (MAPKKK) inhibitor (IC50 = 8 nM). Displays > 33-fold and > 62-fold selectivity over MEKK1 and MEKK4 respectively. Inhibits IL-1-induced activation of NF-κB (IC50 = 83 nM) and JNK/p38. Inhibits production of inflammatory mediators, and sensitizes cells to TRAIL- and TNF-α-induced apoptosis in vitro. | |
| BCC7725 | SU 3327 |
| Selective inhibitor of c-Jun N-terminal kinase (JNK) (IC50 = 0.7 μM). Inhibits the protein-protein interaction between JNK and JIP (IC50 = 239 nM). Displays selectivity over p38 MAPK and Akt. Restores insulin sensitivity in a mouse model of type-2 diabetes. | |
| BCC7726 | (R)-DRF053 dihydrochloride |
| Potent, ATP-competitive inhibitor of cyclin-dependent kinase (cdk) and casein kinase 1 (CK1) (IC50 values are 220, 80 and 14 nM for cdk1/cyclin B, cdk5/p25 and CK1 respectively). Selective over GSK-3 αβ (IC50= 4.1 μM). Also shown to inhibit amyloid-β production in N2A-APP695 cells. | |
| BCC7727 | Tramiprosate |
| Highly potent NR2B-selective NMDA receptor antagonist (Ki = 0.8 nM); blocks NR2B-mediated calcium influx in Ltk cells (Ki = 9.7 nM). Selective for NR2B subunit over α1-adrenergic receptors and hERG channels (IC50 values are 730 nM and 2900 nM respectively). Displays efficacy in the rat carrageenan-induced mechanical hyperalgesia assay. | |
| BCC7728 | LY 311727 |
| Selective secreted phospholipase A2 (sPLA2) inhibitor (IC50 values are <1 μM for group IIA and <50 μM for group V). Attenuates VEGF-mediated platelet-activating factor (PAF) synthesis in BAEC and HUVEC cells at a concentration of 100 μM. | |
| BCC7729 | VU 0238429 |
| Selective positive allosteric modulator of M5 receptors (EC50 values are 1.16, >30 and >30 μM at M5, M1 and M3 receptors respectively). Displays no activity at M2 and M4 receptors. | |
| BCC7730 | BPIPP |
| Non-competitive guanylyl cyclase (GC) and adenylyl cyclase (AC) inhibitor. Downregulates cAMP and cGMP synthesis, and suppresses cGMP accumulation in a variety of cell lines (IC50 = 3.4 - 11.2 μM). Inhibits GC-stimulated Cl- transport in vitro and suppresses toxin-induced intestinal fluid accumulation in vivo. | |
